# US 2004/0064039 A1 · Myocardial perfusion imaging method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0064039 A1
- Document ID: US20040064039A1
- Status: Published application
- Kind: A1
- Application number: 10/629,368
- Filed: 2003-07-29
- Published: 2004-04-01
- Earliest claimed: 2002-07-29
- Assignees: CV Therapeutics, Inc.
- Inventors: Luiz Belardinelli
- Web page: https://patentgrep.com/patent/US20040064039A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61B 6/507: {for determination of haemodynamic parameters, e.g. perfusion CT}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging.

## Claims

### Claim 1

A method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 μg of at least one A2A receptor agonist to a human.

### Claim 2 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount that does not exceed about 1000 μg.

### Claim 3 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount ranging from about 10 to about 600 μg.

### Claim 4 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in a single dose.

### Claim 5 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered by iv bolus.

### Claim 6 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount ranging from about 0.05 to about 60 μg/kg and wherein the A2A receptor agonist is administered by iv bolus.

### Claim 7 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount ranging from about 0.1 to about 30 μg/kg wherein the A2A receptor agonist is administered by iv bolus.

### Claim 8 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount no greater than about 20 μg/kg to a supine patient and wherein the A2A receptor agonist is administered by iv bolus.

### Claim 9 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount no greater than about 10 μg/kg to a standing patient wherein the A2A receptor agonist is administered by iv bolus.

### Claim 10 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount ranging from about 10 to about 600 μg wherein the wherein the A2A receptor agonist is administered in about 20 seconds.

### Claim 11 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount ranging from about 10 to about 600 μg wherein the A2A receptor agonist is administered in less than about 10 seconds.

### Claim 12 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount greater than about 100 μg.

### Claim 13 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount no greater than 600 μ.

### Claim 14 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount no greater than 500 μg.

### Claim 15 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is administered in an amount ranging from about 100 μg to about 500 μg.

### Claim 16 (depends on 1)

The method of claim 1 wherein the A2A receptor agonist is selected from the group consisting of CVT-3033, CVT-3146 and combinations thereof.

### Claim 17

A method of myocardial perfusion imaging of a human, comprising administering a radionuclide and a A2A receptor agonist to the human wherein the myocardium is examined for areas of insufficient blood flow following administration of the radionuclide and the A2A receptor agonist.

### Claim 18 (depends on 17)

The method of claim 17 wherein the myocardium examination begins within about 1 minute from the time the A2A receptor agonist is administered.

### Claim 19 (depends on 17)

The method of claim 17 wherein the administration of the A2A receptor agonist causes at least a 2.5 fold increase in coronary blood flow.

### Claim 20 (depends on 17)

The method of claim 17 wherein the administration of the A2A receptor agonist causes at least a 2.5 fold increase in coronary blood flow that is achieved within about 1 minute from the administration of the A2A receptor agonist.

### Claim 21 (depends on 17)

The method of claim 17 wherein the radionuclide and the A2A receptor agonist are administered separately.

### Claim 22 (depends on 17)

The method of claim 17 wherein the radionuclide and the A2A receptor agonist are administered simultaneously.

### Claim 23 (depends on 17)

The method of claim 17 wherein the administration of the A2A receptor agonist causes at least a 2.5 fold increase in coronary blood flow for less than about 5 minutes.

### Claim 24 (depends on 17)

The method of claim 17 wherein the administration of the A2A receptor agonist causes at least a 2.5 fold increase in coronary blood flow for less than about 3 minutes.

### Claim 25 (depends on 17)

The method of claim 17 wherein the A2A receptor agonist is CVT-3146 which is administered in an amount ranging from about 10 to about 600 μg in a single iv bolus.

### Claim 26 (depends on 25)

The method of claim 25 wherein CVT-3146 is administered in an amount ranging from about 100 to about 500 μg in a single iv bolus.

### Claim 27 (depends on 17)

The method of claim 17 wherein the a A2A receptor agonist is CVT-3146 which is administered in a single dose in an amount ranging from 10 to about 600 μg that is independent of the weight of the human being dosed.

### Claim 28 (depends on 27)

The method of claim 27 wherein the dose is administered in about 30 seconds or less.

### Claim 29 (depends on 27)

The method of claim 27 wherein the dose is administered in about 20 seconds or less.

### Claim 30 (depends on 17)

The method of claim 17 wherein the A2A receptor agonist is administered in a single dose.
